I-Mab

I-Mab Sponsored ADR represents American Depositary Receipts (ADRs) for I-Mab, a biopharmaceutical company that focuses on the discovery and development of innovative biotherapeutics. By utilizing ADRs, I-Mab enables U.S. investors to trade its stock on an American exchange, thereby increasing accessibility to its shares and expanding its investor base beyond its home market in China. I-Mab specializes in cutting-edge treatments primarily targeting cancer and autoimmune diseases, advancing a diversified pipeline of monoclonal antibodies and novel bispecific antibodies. The company is committed to addressing medical needs in oncology and immunology through research partnerships and clinical trials. I-Mab's presence as a Sponsored ADR in the U.S. market highlights its role in bridging international pharmaceutical innovations with American capital markets, facilitating increased funding and global collaboration in its pursuit of medical advancements.